Clinical Trial Update: An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) [Phase 3]

View source ↗

Summary

Phase 3 extension trial evaluating safety of re-dosing with iron isomaltoside/ferric derisomaltose (Monofer/Monoferric) for iron deficiency anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• MONOFERRIC (FERRIC DERISOMALTOSE)
• Monofer (Ferric derisomaltose)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Iron Deficiency Anemia, Iron Deficiency Anaemia | Phase 3 | Status: COMPLETED | Results posted: 2020-03-10